Última actualización 5 de julio de 2026
Key finding
Weight decreased by 3.1 kg (p = 0.001)
The AWARD-11 trial compared the effects of Dulaglutide 3.0 mg and 4.5 mg to 1.5 mg on body weight in patients with type 2 diabetes, finding significant weight reductions.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
High Risk
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The AWARD-11 trial compared the effects of Dulaglutide 3.0 mg and 4.5 mg to 1.5 mg on body weight in patients with type 2 diabetes, finding significant weight reductions.
Weight management is crucial for patients with type 2 diabetes as it can improve glycemic control and reduce the risk of complications. The findings from this trial suggest that higher doses of Dulaglutide may offer a more effective option for weight loss, potentially leading to better overall health outcomes for patients.
The study's population may not be representative of all patients with type 2 diabetes. Long-term effects and safety of higher doses were not assessed. The trial did not include a placebo group for comparison.
Published in
Publication details and source links for this paper.
Enzo B, Juan PF, Francisco JT, et al. Dulaglutide 3.0 and 4.5 mg versus 1.5 mg on body weight in patients with type 2 diabetes: AWARD-11 trial. Diabetes, Obesity & Metabolism. 2021;23(10):2242-2250. doi:10.1111/dom.14465
Dulaglutide 3.0 mg showed a weight decrease of 4.0 kg (p < 0.001).
Dulaglutide 4.5 mg resulted in a weight decrease of 4.7 kg (p < 0.001).
A higher proportion of patients achieved weight loss ≥5% with higher doses.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Dulaglutide, Dulaglutiden dose and Activities of daily living, BMI, HbA1c, and 1 more.
This study contributes evidence to
Primary intervention
Dulaglutide
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
8
Evidence pairs
546
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Guardar evidencia
Relación de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Dulaglutide → Activities of daily living
Dulaglutide → Activities of daily living
Dulaglutiden dose → Activities of daily living
Dulaglutiden dose → Activities of daily living
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Mass Index.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Body Mass Index
Measures Body Mass Index as a key outcome.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
All studies on Dulaglutiden dose
Contributes to Dulaglutiden dose evidence base.
Jump to pre-filtered views in Evidence Explorer.
3 results
3 results
3 results
1 results
3 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 29 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists appears to improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Weight change
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 30 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
BMI
EvidenceScore™ Strong | EvidenceScore™ 75.4 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 15 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Activities of Daily Living.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Activities of daily living
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
